Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Short QT syndrome.

Rainer Schimpf1, Christian Wolpert, Fiorenzo Gaita

  • 11st Department of Medicine-Cardiology, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany. rainer.schimpf@med.ma.uni-heidelberg.de

Cardiovascular Research
|May 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physical activity and Brugada ECG pattern during 12-lead Holter monitoring.

The Journal of sports medicine and physical fitness·2026
Same author

Supraventricular tachycardias in ion channel diseases.

Herzschrittmachertherapie & Elektrophysiologie·2026
Same author

A Novel Variant in SLC4A3 Gene Mutation Associated With Familial Short QT Syndrome and Sudden Death.

Journal of cardiovascular electrophysiology·2025
Same author

The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Working Group on Cardiovascular Pharmacotherapy, the Association of European Paediatric and Congenital Cardiology (AEPC), the Paediatric & Congenital Electrophysiology Society (PACES), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2025
Same author

A Vision Transformer Model for the Prediction of Fatal Arrhythmic Events in Patients with Brugada Syndrome.

Sensors (Basel, Switzerland)·2025
Same author

Incidence of spontaneous Brugada ECG during follow-up in patients with drug-inducible pattern: A systematic review and meta-analysis.

Heart rhythm·2025
Same journal

YAP plays a critical role in myocardial recovery from myocarditis by suppressing IFN-γ signaling pathway.

Cardiovascular research·2026
Same journal

Metabolic crisis and TRPM4 activation cause QT prolongation in TANGO2 deficiency disorder.

Cardiovascular research·2026
Same journal

Personalizing Atrial Fibrillation Therapy: Moving from Genetic Association to Mechanistic Translation.

Cardiovascular research·2026
Same journal

Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension.

Cardiovascular research·2026
Same journal

Endothelial-to-mesenchymal transition (EndMT) in atherosclerosis: mechanisms, models and therapies.

Cardiovascular research·2026
Same journal

The gut-heart axis in cardio-oncology.

Cardiovascular research·2026
See all related articles

Short QT syndrome, a genetic heart condition, increases sudden cardiac death risk. Quinidine shows promise in managing arrhythmias and prolonging the QT interval, offering an alternative to implantable cardioverter-defibrillators.

Area of Science:

  • Cardiology
  • Genetics
  • Electrophysiology

Background:

  • Short QT syndrome (SQTS) is a rare genetic disorder linked to a high risk of sudden cardiac death, syncope, and atrial fibrillation.
  • Patients exhibit corrected QT intervals below 320 ms, indicating a significant electrical abnormality.
  • Genetic mutations in KCNH2, KCNQ1, and KCNJ2 genes have been identified, confirming the disease's genetic heterogeneity and gain-of-function mechanisms.

Purpose of the Study:

  • To investigate the genetic basis and clinical manifestations of Short QT syndrome.
  • To evaluate the efficacy of various antiarrhythmic drugs in managing SQTS.
  • To explore therapeutic strategies, including quinidine, as an alternative or adjunct to implantable cardioverter-defibrillators.

Main Methods:

  • Genetic analysis of affected families to identify mutations in ion channel genes.

Related Experiment Videos

  • Electrophysiological studies to assess the impact of mutations on ion channel function.
  • Clinical evaluation of drug efficacy, including QT interval measurements and arrhythmia induction/suppression.

    • Main Results:

    • Gain-of-function mutations in KCNH2 (HERG), KCNQ1, and KCNJ2 genes were confirmed as causes of SQTS.
    • Ventricular tachyarrhythmias in SQTS may stem from transmural dispersion of repolarization.
    • Quinidine effectively suppressed gain-of-function in I(Kr), prolonged the QT interval, and rendered ventricular tachycardias/fibrillation non-inducible in patients with HERG mutations.

    Conclusions:

    • Short QT syndrome is a genetically diverse condition predisposing to life-threatening arrhythmias.
    • Quinidine demonstrates significant potential in managing SQTS by normalizing electrophysiological parameters and suppressing arrhythmias.
    • Quinidine may serve as a crucial alternative or adjunct therapy, particularly for pediatric patients, mitigating risks associated with implantable cardioverter-defibrillators.